Gossamer Bio submits FDA NDA for seralutinib in pulmonary arterial hypertension
Bitget2026/09/23 20:01- Gossamer Bio submitted a New Drug Application to the FDA in September 2026 for seralutinib to treat pulmonary arterial hypertension.
- The filing is backed by the Phase 3 PROSERA study, with confirmatory evidence from the Phase 2 TORREY study.
- The FDA is expected to decide on acceptance for filing later this year.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
